Multiple Myeloma: Minimal Residual Disease Testing as an End Point Treatment

CureTalks

AUGUST 30, 2017

UPCOMING /Recent Talks

Multiple Myeloma: Minimal Residual Disease Testing as an End Point Treatment

with Dr. Ola Landgren

August 31st, 2017. 6PM EST

Most multiple myeloma patients, even those in complete response, may show signs of relapse at some point of time. So testing and quantifying Minimal Residual Disease (MRD) has become essential to obtain better prognostic correlations. Researchers believe that MRD testing could help them compare myeloma therapy strategies, evaluate new treatments faster, and guide treatment decisions. The myeloma panelists are talking to Dr. Ola Landgren, a lead researcher in the field, on what MRD testing could mean to your treatment, and about how it could become a new and earlier end-point in myeloma treatment.

Panelists

Dr. Ola Landgren

Gary Petersen

Jack Aiello

Cynthia Chmielewski

Matt Goldmann

Novel Technologies to Check Male Fertility Status
with Dr. Jamin Brahmbhatt

July 14th, 2017. 1PM EST

LISTEN

Male factor infertility accounts for 50% of total cases of troubled conception. Unfortunately, male infertility is not as promptly reported as female infertility which is tracked by Society for Assisted Reproductive Technology database. One key reason for under-reporting of male infertility is lesser availability of means of tracking it. When it comes to fertility testing, where women have quite a few over the counter products, men have very few options. Curetalks male fertility advocates and panelists Kristen Darcy, Sara Naab, and Jonathan Boldt are talking to Dr. Jamin Brahmbhatt to learn about new options available for men and also discuss novel advancements in techniques to check male fertility status.

Panelists

Dr. Jamin Brahmbhatt

Kristen Darcy

Sara Naab

Jonathan Boldt

Shweta Mishra

Modern Imaging Techniques in the Diagnosis and Management of Prostate Cancer
with Dr. Antonio Carlos Westphalen

July 27th, 2017. 8PM EST

LISTEN

Multiparametric MRI (mpMRI) is being considered as a game-changer in prostate cancer treatment and management. Our prostate cancer panel of Mike Scott, Tony Crispino, Allen Edel and Joel Nowak is talking to Dr. Antonio Westphalen about the current roles of MRI and mpMRI in diagnosis and management of prostate cancer. The panel will touch upon current roles of older forms of bone scanning and CT, as well as, discuss the evolving roles of newer imaging techniques in the diagnosis and management of high risk and metastatic prostate cancer. Issues on access to high quality imaging and role of the expert uro-radiologists in the diagnosis and management of prostate cancer are some of the other aspects that will be covered in this discussion. Panelists